Xiaochang Qiu1, Haoran Zhang2, Yongheng Zhao3, Jing Zhao4, Yunyan Wan4, Dezhi Li4, Zhouhong Yao5, Dianjie Lin6. 1. Shandong First Medical University Affiliated Provincial Hospital, Shandong First Medical University, Jinan, 250021, Shandong Province, People's Republic of China. 2. Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250021, Shandong Province, People's Republic of China. 3. Shandong University, Cheeloo College of Medicine, Jinan, 250021, Shandong Province, People's Republic of China. 4. Shandong First Medical University Affiliated Provincial Hospital, Jinan, 250021, Shandong Province, People's Republic of China. 5. Shandong First Medical University Affiliated Provincial Hospital, Jinan, 250021, Shandong Province, People's Republic of China. yaozhouhong@163.com. 6. Shandong First Medical University Affiliated Provincial Hospital, Jinan, 250021, Shandong Province, People's Republic of China. lindianjie@126.com.
Abstract
PURPOSE: Lung cancer is the leading cause of cancer-related death worldwide. The early detection of lung cancer is crucial for the diagnosis of this disease. Therefore, an effective and noninvasive method for the early diagnosis of lung cancer is urgently needed. METHODS: To evaluate the diagnostic performance of circulating genetically abnormal cells (CACs) in early lung cancer, a total of 63 participants who completed CAC detection by Zhuhai SanMed Biotech Inc. and obtained pathological results from January to December 2020 were included in our study; 50 patients had lung cancer and 13 patients had benign lung disease. The levels of lung cancer-related markers in peripheral blood and the chest computed tomography (CT) imaging characteristics of these patients were collected before pathological acquisition. RESULTS: The positive rate of CAC was 90.0% in the lung cancer group and 23.1% in the benign lung disease group, and the difference was statistically significant (P < 0.01). The area under the receiver operating characteristic (ROC) curve of CAC was 0.837, the sensitivity was 90%, and the specificity was 76.9%. The area under the ROC curve and sensitivity were both higher than those of the combined or single serum tumor marker test. CONCLUSIONS: This study preliminarily concludes that the CAC test, as a noninvasive test, has high sensitivity and specificity for the early diagnosis of lung cancer. This test is expected to help with the early detection of disease in lung cancer patients.
PURPOSE: Lung cancer is the leading cause of cancer-related death worldwide. The early detection of lung cancer is crucial for the diagnosis of this disease. Therefore, an effective and noninvasive method for the early diagnosis of lung cancer is urgently needed. METHODS: To evaluate the diagnostic performance of circulating genetically abnormal cells (CACs) in early lung cancer, a total of 63 participants who completed CAC detection by Zhuhai SanMed Biotech Inc. and obtained pathological results from January to December 2020 were included in our study; 50 patients had lung cancer and 13 patients had benign lung disease. The levels of lung cancer-related markers in peripheral blood and the chest computed tomography (CT) imaging characteristics of these patients were collected before pathological acquisition. RESULTS: The positive rate of CAC was 90.0% in the lung cancer group and 23.1% in the benign lung disease group, and the difference was statistically significant (P < 0.01). The area under the receiver operating characteristic (ROC) curve of CAC was 0.837, the sensitivity was 90%, and the specificity was 76.9%. The area under the ROC curve and sensitivity were both higher than those of the combined or single serum tumor marker test. CONCLUSIONS: This study preliminarily concludes that the CAC test, as a noninvasive test, has high sensitivity and specificity for the early diagnosis of lung cancer. This test is expected to help with the early detection of disease in lung cancer patients.
Authors: Michael K Gould; Tania Tang; In-Lu Amy Liu; Janet Lee; Chengyi Zheng; Kim N Danforth; Anne E Kosco; Jamie L Di Fiore; David E Suh Journal: Am J Respir Crit Care Med Date: 2015-11-15 Impact factor: 21.405
Authors: Brett W Carter; John P Lichtenberger; Marcelo K Benveniste; Patricia M de Groot; Carol C Wu; Jeremy J Erasmus; Mylene T Truong Journal: Radiographics Date: 2018 Mar-Apr Impact factor: 5.333
Authors: Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks Journal: N Engl J Med Date: 2011-06-29 Impact factor: 91.245
Authors: Ilana F Gareen; Fenghai Duan; Erin M Greco; Bradley S Snyder; Phillip M Boiselle; Elyse R Park; Dennis Fryback; Constantine Gatsonis Journal: Cancer Date: 2014-07-25 Impact factor: 6.860
Authors: Joshua D Cohen; Lu Li; Yuxuan Wang; Christopher Thoburn; Bahman Afsari; Ludmila Danilova; Christopher Douville; Ammar A Javed; Fay Wong; Austin Mattox; Ralph H Hruban; Christopher L Wolfgang; Michael G Goggins; Marco Dal Molin; Tian-Li Wang; Richard Roden; Alison P Klein; Janine Ptak; Lisa Dobbyn; Joy Schaefer; Natalie Silliman; Maria Popoli; Joshua T Vogelstein; James D Browne; Robert E Schoen; Randall E Brand; Jeanne Tie; Peter Gibbs; Hui-Li Wong; Aaron S Mansfield; Jin Jen; Samir M Hanash; Massimo Falconi; Peter J Allen; Shibin Zhou; Chetan Bettegowda; Luis A Diaz; Cristian Tomasetti; Kenneth W Kinzler; Bert Vogelstein; Anne Marie Lennon; Nickolas Papadopoulos Journal: Science Date: 2018-01-18 Impact factor: 47.728